Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.

[1]  L. Wilkins.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.

[2]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[3]  V. Fuster,et al.  Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. , 1994, Circulation.

[4]  L. Wilkins.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.

[5]  K. Mann,et al.  The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes , 1994, Coronary artery disease.

[6]  P. Théroux,et al.  A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. , 1994, Circulation.

[7]  J. Koyama,et al.  Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. , 1994, Journal of the American College of Cardiology.

[8]  H. Weisman,et al.  Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina , 1994, Circulation.

[9]  F. Werf,et al.  A heparin-controlled study of MK-383 in unstable angina , 1994 .

[10]  R. Kronmal,et al.  Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. , 1994, Circulation.

[11]  J. Loscalzo,et al.  Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. , 1993, The American journal of cardiology.

[12]  D. Waters,et al.  Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina , 1993, Circulation.

[13]  M. Juneau,et al.  Initial Experience With a Direct Antithrombin, Hirulog, in Unstable Angina Anticoagulant, Antithrombotic, and Clinical Effects , 1993, Circulation.

[14]  E. Topol,et al.  Use of A Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplast , 1993, Circulation.

[15]  L. Wilkins.  Early Effects of Tissue‐Type Plasminogen Activator Added to Conventional Therapy on the Culprit Coronary Lesion in Patients Presenting With Ischemic Cardiac Pain at Rest Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trialx , 1993, Circulation.

[16]  M. Simoons,et al.  Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). , 1992, Journal of the American College of Cardiology.

[17]  D. Waters,et al.  Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.

[18]  J. Hsia,et al.  Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. , 1992, Journal of the American College of Cardiology.

[19]  Y. Uchida,et al.  Percutaneous coronary angioscopy. , 1992, Japanese heart journal.

[20]  C. Kessler,et al.  Platelet‐Dependent Thrombin Generation After In Vitro Fibrinolytic Treatment , 1992, Circulation.

[21]  M. Pfisterer,et al.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.

[22]  K. Mizuno,et al.  Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. , 1992, The New England journal of medicine.

[23]  J. Ware,et al.  Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator , 1992 .

[24]  C. Madden.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .

[25]  J. Hirsh,et al.  A standard heparin nomogram for the management of heparin therapy. , 1991, Archives of internal medicine.

[26]  D. Tate,et al.  Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[27]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[28]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[29]  W. Guerra.  Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina , 1990 .

[30]  R. Abbate,et al.  Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina , 1990, The Lancet.

[31]  R. Bar-Shavit,et al.  Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. , 1989, The Journal of clinical investigation.

[32]  D. Doyle,et al.  Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. , 1989, The New England journal of medicine.

[33]  K. Mann,et al.  Activation/inactivation of human factor V by plasmin. , 1989, Blood.

[34]  P. Armstrong,et al.  Angiographic morphology in unstable angina pectoris. , 1988, The American journal of cardiology.

[35]  P. Théroux,et al.  Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.

[36]  V. Fuster,et al.  Importance of adequate heparin dosage in arterial angioplasty in a porcine model. , 1988, Circulation.

[37]  D. Graham.  Detailed diagnoses and procedures for patients discharged from short-stay hospitals. , 1988, Vital and health statistics. Series 13, Data from the National Health Survey.

[38]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[39]  L Morgenstern,et al.  Coronary angioscopy in patients with unstable angina pectoris. , 1986, The New England journal of medicine.

[40]  V. Fuster,et al.  Angiographic evolution of coronary artery morphology in unstable angina. , 1986, Journal of the American College of Cardiology.

[41]  D. Sackett,et al.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. , 1985, The New England journal of medicine.

[42]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[43]  M J Davies,et al.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. , 1984, The New England journal of medicine.

[44]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[45]  N. Wolf,et al.  Intracoronary thrombus in nontransmural myocardial infarction and in unstable angina pectoris. , 1983, The American journal of cardiology.

[46]  R. Rosenberg,et al.  Protection of factor Xa from neutralization by the heparin-antithrombin complex. , 1983, The Journal of clinical investigation.

[47]  H. Gold,et al.  Intracoronary thrombolysis in syndromes of unstable ischemia: angiographic and clinical results. , 1982, American heart journal.

[48]  A. Telford,et al.  TRIAL OF HEPARIN VERSUS ATENOLOL IN PREVENTION OF MYOCARDIAL INFARCTION IN INTERMEDIATE CORONARY SYNDROME , 1981, The Lancet.

[49]  M. Sekiguchi,et al.  Coronary thrombosis in pathogenesis of acute myocardial infarction. Histopathological study of coronary arteries in 108 necropsied cases using serial section. , 1978, British heart journal.

[50]  G. Hutchins,et al.  The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. , 1977, American heart journal.

[51]  W. Hoyt,et al.  Letter: Suprastriate hemianopia. , 1974, Lancet.

[52]  J. Hirsh,et al.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. , 1972, The New England journal of medicine.

[53]  R. Vakil,et al.  PREINFARCTION SYNDROME--MANAGEMENT AND FOLLOW-UP. , 1964, The American journal of cardiology.

[54]  P. Wood.  Acute and Subacute Coronary Insufficiency* , 1961, British medical journal.

[55]  R. Beamish,et al.  Impending myocardial infarction. Recognition and management. , 1960 .

[56]  G. Casten,et al.  Virtue of prompt anticoagulant therapy in impending myocardial infarction: experiences with 318 patients during a 10-year period. , 1959, Annals of internal medicine.